top of page
  • Available
    • Mar 1, 2022

NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

elranatamab

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)


Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma


Sponsor

Pfizer


Collaborator

In Expanded Access, treating physicians are the Sponsors

 

ClinicalTrials.gov Identifier: NCT05238311

NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

First Posted : February 14, 2022

Click here for details on Clinicaltrials.gov